ArticleInfectious medicine2025
Pentavalent rotavirus vaccine effectiveness among children in Shenzhen, China: A population-based test-negative design with directed acyclic graphs bias adjustment.
Article in Infectious medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: China's Notifiable Disease Reporting System comprehensively collects data on pediatric acute gastroenteritis cases from all levels of healthcare. This study evaluated the effectiveness of the pentavalent rotavirus vaccine against rotavirus gastroenteritis in children under five years of age during seasonal epidemic periods. Methods: Using a test-negative design, we analyzed laboratory data from diarrhea patients aged 2-59 months who sought medical care in Longhua District, Shenzhen, Guangdong Province, China between January 2020 and March 2024. Vaccination history and potential confounders, including sex, household registration status, prematurity, and birth weight, were collected retrospectively. Directed acyclic graphs were used to identify adjustment variables. Vaccine effectiveness was calculated as (1 - adjusted odds ratio) × 100% using unconditional logistic regression, comparing rotavirus-positive cases with rotavirus-negative controls. Results: The incidence of rotavirus gastroenteritis peaked and then progressively declined from January 2020 through March 2023, with no seasonal resurgence observed in the first quarter of 2023. Analysis of 928 epidemic-season cases (674 RV+; 254 RV-) revealed an overall pentavalent rotavirus (RV5) vaccine effectiveness of 79.6% (95% CI: 68.9%-86.6%). Dose-specific vaccine effectiveness varied substantially: 1 dose vaccine effectiveness registered at 26.7% (95% CI: -162.1%-79.5%), rising to 76.6% (95% CI: 46.2%-89.8%) for 2 doses, and reaching 82.7% (95% CI: 72.2%-89.2%) for 3 doses. Age-stratified analysis showed vaccine effectiveness of 79.5% (95% CI: 56.8%-90.3%) in children aged 2-11 months, 83.8% (95% CI: 66.4%-92.2%) for 12-23 months, and 79.6% (95% CI: 68.9%-86.6%) in those aged 24-35 months, while vaccine effectiveness was 31.2% (95% CI: -251.8%-86.5%) in children aged 36-59 months. Conclusions: A three-dose regimen of pentavalent rotavirus vaccine provides significant effectiveness against rotavirus gastroenteritis for children under 36 months of age during epidemic seasons, thereby alleviating the burden on public health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.